Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 -- Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million for the Fourth Quarter 2022 -- GAAP Diluted EPS of $(0.09) for the Fourth Quarter of 2...
Source: pharmiweb.com